Voxelotor Sickle Cell Exercise Study

• Status: Recruiting
• Trial end date: 2021-09-20
• Target enrollment: 0
• Participant gender: All

Summary

This study is a pilot, open-label, single-arm study to evaluate the effect of the sickle cell medication voxelotor on exercise capacity, as measured by cardiopulmonary exercise testing (CPET) in patients 12 years of age and older with sickle cell anemia (SCA).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Elizabeth Yang; Elizabeth Yang, MD, PhD
• Collaborators: Global Blood Therapeutics; Mednax Center for Research, Education, Quality and Safety; University of California, San Francisco

Criteria

Inclusion Criteria:

1. Provision of signed and dated informed consent form

2. Stated willingness to comply with all study procedures and availability for the duration of the study

3. Male or female, age > 12 years

4. In good general health as evidenced by medical history and diagnosed with a genetically severe form of sickle cell anemia (Hgb SS, Hgb S beta 0 thalassemia, Hgb SCHarlem, and others)

5. Patients who are on Hydroxyurea need to be on a stable dose for at least 3 months without anticipated change in dosing until the study is completed.

6. Ability to take oral medication and willingness to adhere to daily voxelotor and 2 CPETs at scheduled intervals.

7. For females of reproductive potential who are sexually active: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 30 days after the end of study.

8. For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner

Exclusion Criteria:

1. Patients on chronic transfusions or who received a transfusion within last 8 weeks

2. Patients who had hospitalization for vaso-occlusive crisis or acute chest syndrome within 30 days prior to informed consent/assent.

3. Patients who have screening alanine aminotransferase (ALT) > 4X upper limit of normal

4. Patients who suffer from physical inactivity attributable to clinically significant musculoskeletal, cardiovascular, or respiratory comorbidities

5. Patients already taking commercially available voxelotor

6. Prior hypersensitivity to voxelotor or excipients.

7. Pregnant patients